Cash, cash equivalents and marketable securities. As of December 31, 2023, the Company had $234.1 million in cash, cash equivalents and marketable securities, providing cash runway into the first half of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FHTX:
- Foghorn Therapeutics, Eli Lilly to present new preclinical data at AACR
- Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
- Is FHTX a Buy, Before Earnings?
- Foghorn’s FHD-909 Advances to Clinical Trials with Eli Lilly
- Foghorn Therapeutics Releases New Investor Presentation
